



FOR IMMEDIATE RELEASE ON August 15, 2024

Flamma Enters Cooperative Agreement with Seven Star Pharmaceutical Services to Expand Solid State Services

Chignolo D'Isola, Bergamo, Italy – August 15, 2024 – The **Flamma Group** (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, announced a cooperative agreement with Seven Star Pharmaceutical Services (SS) to expand its solid state science services.

This collaboration will allow Flamma to service customers more effectively by identifying the proper version of their API. By looking at a variety of areas such as salt & co-crystal selection, crystallization development, polymorph investigation, and pre-formulation evaluation, this partnership will look to solve typical problematic areas in the development of new drugs.

Gianmarco Negrisoli, President Flamma USA, commented “We have been working with Seven Star for several years and felt that it was time to formalize our collaboration. The proximity to Flamma USA coupled with the expertise in house at Seven Star will be beneficial to existing and new customers. Solving crystallization issues early on can speed development and scale up which, in turn, is beneficial to all parties involved.”

“Working with the Flamma USA team has been rewarding. Our ability to turn projects around quickly has helped their customers succeed in their attempts to get their molecule into the clinic. We are very proud to be part of the process to bring new drugs forward,” says Sathyanarayana ‘Reddy’ Perumalla, Ph.D., Founder and Director, Seven Star Pharmaceutical Services.

Flamma USA offers customers an easy entry point into the Flamma Group. Specializing on early stage & pre-clinical development of new drugs, the Malvern, PA facility can leverage Flamma Italy and Flamma Honkai to provide multiple options for securing ones supply chain. Learn more at FlammaGroup.com



Flamma contact: Kenneth Drew, Ph.D., VP Flamma USA
ph. 1-617-515-0975 or email: ken.drew@flammagroup.com

About Flamma:

FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of small molecule APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has five manufacturing facilities- Italy (3), China, and the USA. The cGMP Italian locations (Chignolo, Isso and Bulciago) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, is a cGMP manufacturing facility that has been inspected by Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer's compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Flamma USA (Malvern, PA near Philadelphia) services customers looking to keep their pre-clinical/early stage clinical small molecule drug development in the USA. Flamma USA also offers the ability to handle HPAPIs as well as low volume commercial materials.

As a fully integrated company, Flamma can move customer compounds quickly along their journey by taking into consideration all aspects necessary for the success of customer's projects while providing supply chain security.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 1,100 m³ and over 850 employees, see why Flamma should be your next contract manufacturer.

FLAMMA - THE THINKING CDMO™.

<https://www.flammagroup.com/>

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>



About Seven Star Pharmaceutical Services:

Seven Star Pharmaceutical Services (Seven Star) is a technology-driven Contract Research Organization (CRO) that supports drug development programs. They work closely with clients to ensure comprehensive solutions for their needs in CMC/solid-state chemistry research, crystallization process development along with preformulation studies and formulation development. In addition to these services, they also provide routine analytical testing, CMC consulting, intellectual property support and structure determination from single crystal X-ray diffraction data.